5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E)
    Meeting Abstract

    Armstrong, A. J.; Halabi, S.; Luo, J.; Nanus, D. M.; Giannakakou, P.; Szmulewitz, R. Z.; Danila, D. C.; Healy, P.; Anand, M.; Rothwell, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: An Alliance Foundation trial (AFT-19)
    Meeting Abstract

    Aggarwal, R. R.; Eggener, S. E.; Chen, R. C.; Heller, G.; Patnaik, A.; Xiao, H.; Weckstein, D.; Mohler, J.; Watson, M.; Taplin, M. E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Microsatellite instability in prostate cancer and response to immune checkpoint blockade
    Meeting Abstract

    Abida, W.; Cheng, M. L.; Armenia, J.; Middha, S.; Autio, K. A.; Rathkopf, D. E.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Carbone, E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Assessing the quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) in immuno-oncology (I/O): An application to nivolumab vs. everolimus in previously treated advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Shah, R.; Botteman, M.; Solem, C.; Luo, L.; Doan, J.; Cella, D.; Motzer, R. J.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Regulation of the tumor suppressor PLZF and prostate cancer prognosis
    Meeting Abstract

    Stopsack, K. H.; Gerke, T. A.; Tyekucheva, S.; Mucci, L. A.; Kantoff, P. W.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Incorporation of PBRM1, BAP1, TP53 mutation status into the Memorial Sloan Kettering Cancer Center (MSKCC) risk model: A genomically annotated tool to improve stratification of patients (pts) with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Voss, M. H.; Cheng, Y.; Marker, M.; Kuo, F.; Choueiri, T. K.; Hsieh, J. J.; Reising, A.; Motzer, R. J.; Hakimi, A. A.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in prostate cancer
    Meeting Abstract

    Mazzu, Y. Z.; Gerke, T. A.; Chakraborty, G.; Armenia, J.; Atiq, M. O.; Komura, K.; Yoshikawa, Y.; Lee, G. S. M.; Mucci, L. A.; Kantoff, P. W.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Immunotherapy for biochemically recurrent prostate cancer
    Meeting Abstract

    Madan, R. A.; Karzai, F.; Bilusic, M.; Strauss, J.; Slovin, S. F.; Harshman, L. C.; Theoret, M. R.; Arlen, P. M.; Rauckhorst, M.; Couvillon, A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Early versus delayed initiation of salvage androgen deprivation therapy and the risk of prostate cancer-specific mortality
    Meeting Abstract

    Mahal, B. A. V.; Chen, M. H.; Renshaw, A. A.; Kantoff, P. W.; D'Amico, A. V.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials
    Meeting Abstract

    Pond, G. R.; Sonpavde, G.; Fizazi, K.; De Bono, J. S.; Basch, E. M.; Scher, H. I.; Smith, M. R.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save